Linfei Hu

643 total citations
34 papers, 451 citations indexed

About

Linfei Hu is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Linfei Hu has authored 34 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Cancer Research. Recurrent topics in Linfei Hu's work include Thyroid Cancer Diagnosis and Treatment (11 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer-related Molecular Pathways (5 papers). Linfei Hu is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (11 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer-related Molecular Pathways (5 papers). Linfei Hu collaborates with scholars based in China, United States and Australia. Linfei Hu's co-authors include Ming Gao, Xianhui Ruan, Xiukun Hou, Xiangqian Zheng, Jingtai Zhi, Xi Wei, Jingzhu Zhao, Xianle Shi, Songfeng Wei and Xiangqian Zheng and has published in prestigious journals such as Scientific Reports, ACS Applied Materials & Interfaces and Frontiers in Immunology.

In The Last Decade

Linfei Hu

33 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linfei Hu China 13 268 119 109 104 68 34 451
Liehao Jiang China 12 194 0.7× 125 1.1× 151 1.4× 80 0.8× 55 0.8× 27 430
Nadia Boubekeur France 9 169 0.6× 206 1.7× 83 0.8× 200 1.9× 85 1.3× 11 519
Sébastien L. Floor Belgium 7 264 1.0× 165 1.4× 105 1.0× 180 1.7× 37 0.5× 7 471
Juyong Liang China 10 195 0.7× 88 0.7× 54 0.5× 110 1.1× 74 1.1× 17 371
Gizem Gülfidan Türkiye 12 244 0.9× 85 0.7× 36 0.3× 71 0.7× 83 1.2× 23 397
Guohe Song China 10 216 0.8× 142 1.2× 49 0.4× 131 1.3× 91 1.3× 19 471
Woo-Young Kim South Korea 6 267 1.0× 76 0.6× 66 0.6× 166 1.6× 135 2.0× 6 416
Wen‐Lian Chen China 10 262 1.0× 186 1.6× 52 0.5× 74 0.7× 50 0.7× 20 419
Suguru Hayase Japan 16 282 1.1× 97 0.8× 39 0.4× 193 1.9× 109 1.6× 34 511
Valentina Rossi Italy 9 149 0.6× 94 0.8× 59 0.5× 119 1.1× 134 2.0× 15 369

Countries citing papers authored by Linfei Hu

Since Specialization
Citations

This map shows the geographic impact of Linfei Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linfei Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linfei Hu more than expected).

Fields of papers citing papers by Linfei Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linfei Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linfei Hu. The network helps show where Linfei Hu may publish in the future.

Co-authorship network of co-authors of Linfei Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Linfei Hu. A scholar is included among the top collaborators of Linfei Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linfei Hu. Linfei Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruan, Xianhui, Mei Tao, Linfei Hu, et al.. (2025). Persistent pre-exhausted CD8+ T cells shape the tumor immune microenvironment in anaplastic thyroid cancer. Endocrine Related Cancer. 32(3). 1 indexed citations
2.
Liu, Min, Yu Liu, Yu Zeng, et al.. (2025). Programmed cell death-related gene IL20RA facilitates tumor progression and remodels tumor microenvironment in thyroid cancer. Scientific Reports. 15(1). 3520–3520. 1 indexed citations
3.
Tao, Mei, Xianhui Ruan, Wei Luo, et al.. (2025). Enhancer-mediated NR2F2 recruitment activates BGN to promote tumor growth and shape tumor microenvironment in papillary thyroid cancer. Theranostics. 16(1). 298–324. 1 indexed citations
4.
Gu, Pengfei, Jie Zhao, Wei Zhang, et al.. (2024). An Inducible CRISPR‐dCas9‐Based Transcriptional Repression System for Cancer Therapy. Small Methods. 8(8). e2301310–e2301310. 2 indexed citations
5.
Wang, Yue, et al.. (2024). FATS inhibits the Wnt pathway and induces apoptosis through degradation of MYH9 and enhances sensitivity to paclitaxel in breast cancer. Cell Death and Disease. 15(11). 835–835. 2 indexed citations
6.
Gao, Ying, Xiukun Hou, Yanhui Zhang, et al.. (2024). Multifocality increases the risk of central compartment lymph node metastasis but is not related to the risk of recurrence and death in papillary thyroid carcinoma. Gland Surgery. 13(12). 2383–2394. 1 indexed citations
7.
8.
Hou, Xiukun, Junya Ning, Zhongyu Wang, et al.. (2023). PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause. International Journal of Biological Sciences. 19(12). 3970–3986. 5 indexed citations
9.
Zhi, Jingtai, Linfei Hu, Kang Ning, et al.. (2023). Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis. Cell Death and Disease. 14(3). 224–224. 12 indexed citations
10.
Tang, Tao, Jingtai Zhi, Wei Zhang, et al.. (2022). Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer. Journal of Healthcare Engineering. 2022. 1–9. 2 indexed citations
11.
Hu, Linfei, Kang Ning, Jingtai Zhi, et al.. (2022). Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib. Cell Death and Disease. 13(2). 124–124. 18 indexed citations
12.
Hu, Linfei, Kang Ning, Jingtai Zhi, et al.. (2021). The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification. Annals of Translational Medicine. 9(10). 866–866. 7 indexed citations
13.
Hou, Xiukun, Xianle Shi, Wei Zhang, et al.. (2021). LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma. Cell Death and Disease. 12(4). 347–347. 72 indexed citations
14.
Li, Qiu, Linfei Hu, Huijuan Wang, et al.. (2020). FATS regulates polyamine biosynthesis by promoting ODC degradation in an ERβ-dependent manner in non-small-cell lung cancer. Cell Death and Disease. 11(10). 839–839. 7 indexed citations
15.
Wang, Huijuan, Jingzhu Zhao, Linfei Hu, et al.. (2020). Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway. Frontiers in Oncology. 10. 217–217. 38 indexed citations
16.
17.
Zhang, Jun, Linfei Hu, Huijuan Wang, et al.. (2019). <p>Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma</p>. Cancer Management and Research. Volume 11. 3765–3777. 7 indexed citations
18.
Zhi, Jingtai, Yu Wu, Linfei Hu, et al.. (2019). Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma. International Journal of Clinical Oncology. 25(1). 59–66. 13 indexed citations
19.
Wu, Yu, Huijuan Wang, Jingtai Zhi, et al.. (2019). <p>BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients</p>. OncoTargets and Therapy. Volume 12. 6937–6945. 3 indexed citations
20.
Yang, Yi‐Ju, et al.. (2016). Snail-induced epithelial-mesenchymal transition in gastric carcinoma cells and generation of cancer stem cell characteristics. Genetics and Molecular Research. 15(3). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liehao Jiang Breakdown of academic impact, for papers by Nadia Boubekeur Breakdown of academic impact, for papers by Sébastien L. Floor Breakdown of academic impact, for papers by Juyong Liang Breakdown of academic impact, for papers by Gizem Gülfidan Breakdown of academic impact, for papers by Guohe Song Breakdown of academic impact, for papers by Woo-Young Kim Breakdown of academic impact, for papers by Wen‐Lian Chen Breakdown of academic impact, for papers by Suguru Hayase Breakdown of academic impact, for papers by Valentina Rossi
Rankless by CCL
2026